This video series focuses on the key unmet needs in chronic myeloid leukaemia (CML). In this series we are joined by a host of international experts who provide their perspectives on resistance to tyrosine kinase inhibitors (TKIs), the impact of intolerance on patients and the potential consequences of sequential TKIs use. The series aims to shine a light on how healthcare professionals can provide even better care for patients with CML in later lines of therapy.

 

OVERCOMING RESISTANCE

In this video we are joined by Dr Jorge Cortes (Georgia Cancer Centre, USA) and Dr Carla Boquimpani (Hemario Hospital, Brazil) who discuss the impact of resistance to TKIs on risk of progression and survival in CML.

 
 

MISSING THE MARK IN CML

In this video we are joined by Dr Moshe Talpaz (University of Michigan, USA) and Dr Eri Matsuki (Keio University Hospital, Japan) who consider the impact of treatment-related adverse events on the patient and how these influence treatment decisions in CML.

 
 

APPROACHES IN PATIENT MANAGEMENT

In this video we are joined by Dr Javier Pinilla-Ibarz (Moffit Cancer Centre, USA) and Prof. Antonio Almeida (Hospital da Luz, Portugal) who contemplate the consequences of sequential TKI use in CML and how this can affect the efficacy of treatments in later lines of therapy.

 
Rate this content: 
No votes yet
UK | June 2022 | 196112
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com